Our members make us

Founding Director of the Institute for Aging Research at the Nathan Shock Center of Excellence in the Basic Biology of Aging. Director of the Paul F. Glenn Center for the Biology of Human Aging Research at Albert Einstein College of Medicine.

Co-Founder of Beyond Aging, an organization dedicated to growing the funding environment for longevity research, and CEO of Helpwear, a medical device company building emergency cardiac monitoring devices.

Scientist and entrepreneur known for his discoveries in biophysics and for creating the world's smallest personal computer. CEO of Retro Biosciences.

Since 2020, Rafael Bottos has been the leader of Aptah Bio Inc. Aptah Bio is working in the forefront of a novel and proprietary rejuvenation technology called RNA WiCo™ (RNA Widespread Correction) able to restore overall RNA expression balance and structural integrity, consequently reducing the expression of multiple toxic proteins simultaneously. Working as an alternative method to partial reprogramming, Aptah's technology can rejuvenate fully differentiated cells and overcome most of current challenges, from manufacturing, distribution, safety and efficacy.

Chris Bradley, MS is a serial entrepreneur who has co-founded and run several successful startups including Loki Therapeutics and Mana Health (acquired by Comcast NBC Universal, Inc.). With over 15 years of C-suite experience in tech, health IT, and biotech, Chris is passionate about taking breakthrough ideas and making them a reality. He is a primary inventor of over 20 patents and holds a BS in Neuroscience & Cell Biology from Rutgers University and MS in Computer Science from the New York University.

Russell Dahl is CEO of Neurodon, a biopharmaceutical company developing medicines that target key cellular stress pathways involved in aging, neurodegeneration, and metabolic disease.

Founder, President and Chief Science Officer of LEV Foundation, a California-based 501c3 public charity that conducts and inspires research to comprehensively prevent human age-related disease and disability.

CEO and co-founder at BioAge, a biotechnology company that discovers and develops drugs that treat aging and age-related diseases.

Joel M. Friedman M.D., Ph.D is a Professor and Young Men's Division Chair in Cardiovascular Physiology (Emeritus) at the Albert Einstein College of Medicine and the Scientific Founder, Chief Scientific Officer and Board member of Vascarta.

Founder of the Forever Healthy Foundation and owner of Kizoo Technology Ventures.

Serial biotechnology entrepreneur currently the Co-Founder and CEO of Lygenesis, an organ regeneration company.

Serial entrepreneur, having co-founded 3 deep-tech ventures and raised more than $50 million in venture funding for his own ventures and as an entrepreneur in residence. He has worked with several other early-stage companies in the therapeutics space on fundraising, IP protection, and clinical trial strategies, focusing on early treatments in cardiovascular, oncology, and neurodegenerative spaces. Visiting Lecturer to several universities on VC and intellectual property rights, co-authored a master's program in Technology Law for the Riga Graduate School of Law. Since 2018, he has co-founded medical tech startup Longenesis, a cutting-edge company that unlocks the hidden value of biomedical data and accelerates novel drug treatment & and discovery. In 2021, he co-founded the Longevity Science Foundation, a non-profit organization advancing the field of human longevity by funding research and development of medical technologies to extend the healthy human lifespan. He holds a BSc in International Affairs from Rīga Stradiņš University and two MSc in Political Science and Government and Law and Finance from Central European University and Riga Graduate School of Law, respectively. He was named Forbes Latvia's 30 Under 30 in technology and healthcare in 2020.

Director of National University Health System [NUHS) Centre for Healthy Ageing, Singapore. The former President and CEO of the Buck Institute for Research on Aging.

Dr. Eric Leire is the CEO of Genflow Biosciences, a longevity gene therapy biotech listed on the London Stock Exchange (GENF) and trading on OTC.QB (GENFF). He also serves as the executive chairman of Immunethep (virulence company) and as NED for OSE Immunotherapeutics (oncology), Phaxiam (anti-infective), BSIM Therapeutics (CNS) and Inhatarget (oncology). Eric brings extensive pharma and biotech experience from Pfizer, Schering Plough and Pharmacia and is a Partner at the BioStrategies Group In addition, Eric hold an MD from Grenoble University and an MBA from HEC and Kellogg School of Management, Northwestern University. He is also the inventor of several patents in the pharmaceutical field.

Dr. Joan Mannick is the Co-Founder and CEO of Tornado Therapeutics. Prior to joining Tornado, Dr. Mannick was Head of Research and Development at Life Biosciences, a biotechnology company advancing treatments for age-related diseases by targeting aging biology.

Jerry McLaughlin is Chief Executive Officer and board member of Life Biosciences, Inc. He has over 30 years of experience in the biopharmaceutical industry and has been involved in the discovery, clinical development, and global commercialization of more than a dozen FDA-approved drugs with multiple successful exits.

Biotech investor and entrepreneur, author. Co-founder of Juvenescence and other successful ventures focused on longevity, biotech, and clean food.

Chris Mirabile is Founder and CEO of NOVOS, a Public Benefit Corporation, and the leading consumer longevity biotech, focused on OTC formulations, bioinformatics, and digital resources applied to the context of longevity. Chris' interest in longevity began after being cured of a brain tumor as a teen.

Founder and CEO of Cambrian Biopharma, a Distributed Drug Discovery Company developing therapeutics targeting the biology of aging.

Richard Prince, Ph.D., is the CEO of Now Biopharma. Now Biopharma, LLC, is a Clinical CRO and Life Science Consultancy headquartered in New Jersey, USA. The clinical CRO specializes in performing phase-2 , -3, and -4, acute care clinical trials (e.g., cardiovascular, neurology, infectious disease), while the consultancy provides services in life-science entrepreneurship, C-level management, strategy, scientific affairs, regulatory affairs, clinical development, facilitation, and quality operations. Dr. Prince previously worked at Gibraltar Laboratories (a contract testing laboratory, now part of Nelson Laboratories), Microgen, Inc. (a specialty chemical firm), Mayne Pharma (a generic drug firm, now part of Pfizer), and Prolong Pharmaceuticals (a hematology and oncology biotech startup). He has also consulted extensively for multiple ‘Big Pharma’ companies and is a well-known author and editor within the Parenteral Drug Association (PDA) community, with five published textbooks in the areas of microbiology (two editions), quality, variability, and biotechnology. .

Co-Founder & Managing Director at Apollo Health Ventures, a venture capital fund that invests in early-stage biotech and aging biology companies.

Co-Founder and CEO of Oviva Therapeutics, Director of Women's Health at Cambrian Biopharma.

Sam Sharifi, PhD is a biogerontologist with over a decade of experience in aging research and translation. Prior to Matter Bioworks, Sam was the scientific project manager at Vincere Biosciences, a longevity company developing mitophagy-enhancing compounds. During his academic career, Sam co-authored various longevity research publications including DrugAge, a database of anti-aging drugs. He conducted his PhD research at the FSU Jena and the Leibniz Institute on Aging.

CEO and President of the Buck Institute for Research on Aging and Professor of Medicine at the University of California, San Francisco.

Longevity investor with a mission to extend healthy lifespans of at least one billion people. Co-Founder of BOLD Longevity Growth Fund. Innovation Board Member at XPRIZE Foundation, Development Sponsor of the Healthspan XPRIZE.

Current Founder and CEO of Insilico Medicine, and founder and former CEO of Deep Longevity.

Garri Zmudze is an investor and advisor for deeptech companies developing life-changing solutions across biotech, medicine, longevity and more. Garri is committed to building a world where everyone has more healthy years with their loved ones. Garri is also co-founder and managing partner at LongeVC, a venture capital firm investing in visionary biotech and longevity. Outside of his work with LongeVC, Garri is one of longevity's top angel investors. He has several successful exits across biotech and emerging tech companies, including Insilico Medicine, Deep Longevity and Basepaws.